BioMarin Pharmaceutical Inc expected to post earnings of 69 cents a share - Earnings Preview

BioMarin Pharmaceutical

04/08/2026 22:45

BioMarin Pharmaceutical Inc BMRN.OQ BMRN.O is expected to  show a rise in quarterly revenue when it reports  results on August 6 for the period ending June 30 2026
The San Rafael California California-based  company is expected to report a 12.3% increase in revenue to $926.908 million from $825.41 million a year ago, according to the mean estimate from 21 analysts, based on LSEG data. (Majority are not reflecting for the announced acquisition of Amicus Therapeutics)
​LSEG's mean analyst estimate for BioMarin Pharmaceutical Inc is for earnings of 69 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 21 "strong buy" or "buy," 6 "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for BioMarin Pharmaceutical Inc is $89.66, about 49.4% above its last closing price of $60.00
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
0.73
0.75
0.54
Missed
-28.1
Dec. 31 2026
-0.03
0.62
-0.24
Missed
-138.4
Sep. 30 2025
-0.37
0.37
-0.16
Missed
-143​
Jun. 30 2025
0.87
0.83
1.23
Beat
47.3
​​Mar. 31 2025
0.73
0.71
0.95
Beat
34.1
Dec. 31 2024
0.52
0.53
0.64
Beat
20.8​
Sep. 30 2024
0.50
0.52
0.55
Beat
6.3
Jun. 30 2024
0.37
0.35
0.56
Beat
60.4
This summary was machine generated August 4 at 21:45 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)